Post by Sachs Associates

Perspectum is a global leader in quantitative metabolic imaging, focused on enabling differentiation in the rapidly intensifying obesity and cardiometabolic market. In the GLP-1 era – where weight loss alone is no longer sufficient – sponsors must demonstrate deeper, organ-level impact to compete. Perspectum provides validated imaging biomarkers and integrated trial expertise that generate that evidence. In obesity and related metabolic disease, Perspectum quantifies changes in body composition, muscle, liver, heart, kidney, and pancreas – including adiposity distribution, muscle quality, liver fat, inflammation, fibrosis, and broader cardiometabolic involvement. These data-rich endpoints enable sponsors to demonstrate mechanistic impact, evaluate combination effects, stratify patient populations, and build meaningful differentiation beyond headline efficacy metrics. The company brings extensive experience supporting late-phase metabolic programs, including MASH, alongside proprietary expertise in quantitative inflammation assessment and global multi-center standardization of imaging biomarkers. Through its Pharma Solutions group, Perspectum partners with biopharma sponsors across more than 90 commercial clinical trials in metabolic and inflammatory disease. By integrating proprietary biomarker development with global operational delivery and regulatory expertise, Perspectum helps sponsors strengthen competitive positioning and accelerate evidence generation in obesity drug development. Meet Perspectum Ltd. @ #Sachs_OCIF More Info @ https://lnkd.in/e44tnKf3 #ObesityInnovation #CardiometabolicHealth #MetabolicDiseases #ObesityTreatment #DiabetesCare #GLP1 #CardioMetabolic #LifeSciences #BioPharma #BiotechInvestment #HealthcareInnovation #TherapeuticInnovation #PharmaDeals #BiotechConference #InvestmentOpportunities #MetabolicHealth #NextGenTherapies #ADA2026